NASH: Flying the Plane While Building It
This week, Clarion’s medical director, Amama Sadiq, MD, MPH, published an article in In Vivo, as part of Clarion’s long-standing commitment to advancing the development of novel therapeutics for diseases with high unmet need. This thought piece discusses the key challenges and potential solutions associated with drug development and commercialization in non-alcoholic steatohepatitis (NASH). NASH is an emerging therapeutic area that is currently attracting substantial interest and investment from the biopharma space. A silent epidemic of the western world triggered by a surge in obesity and metabolic risk factors, NASH affects upwards of 10-15 million Americans and (along with its precursor form NAFLD) is estimated to cost the U.S. more than $100B annually. With no approved therapies for this deadly condition, the unmet medical need is exceptionally high.
Read the full article authored by Clarion’s medical director Amama Sadiq, MD, MPH, et al.